Glypican-1-targeted antibody-drug conjugate inhibits the growth of glypican-1-positive glioblastoma

In conclusion, GPC1-ADC demonstrated potent intracranial activity against GPC1-positive glioblastoma in an orthotopic xenograft model. These results indicate that GPC1-ADC could represent a groundbreaking new therapy for treating glioblastoma beyond the BBB.PMID:38417223 | DOI:10.1016/j.neo.2024.100982

Source: Neoplasia - February 28, 2024 Category: Cancer & Oncology Authors: Shun Uchida Satoshi Serada Yuji Suzuki Eiji Funajima Kei Kitakami Kazumasa Dobashi Satomi Tamatani Yuichi Sato Takaaki Beppu Kuniaki Ogasawara Testuji Naka Source Type: research